The aim of this study was to evaluate the prognostic impact of FLT3-ITD in core-binding factor acute myeloid leukemia (CBFAML) in an international, multicenter survey of 97 patients of whom 52% had t(8;21)(q22;q22) and 48% had inv(16)(p13q22)/t(16;16)(p13;q22). The median age of the patients was 53 years (range, 19-81). Complete remission after anthracycline-based induction (n=86) and non-intensive therapy (n=11) was achieved in 97% and 36% of the patients, respectively. The median follow-up was 4.43 years (95% confidence interval [95% CI]: 3.35-7.39 years). The median survival after intensive and non-intensive treatment was not reached and 0.96 years, respectively. Among intensively treated patients, inv(16) with trisomy 22 (n=11) was associated with a favorable 4-year relapse-free survival rate of 80% (95% CI: 59-100%) as compared to 38% (95% CI: 27-54%; P=0.02) in all other patients with CBFAML/ FLT3-ITD (n=75). Overall, 24 patients underwent allogeneic hematopoietic cell transplantation (HCT), 12 in first complete remission and 12 after relapse. Allogeneic HCT in first complete remission was not beneficial (P=0.60); however, allogeneic HCT seemed to improve median survival in relapsed patients compared to that of patients treated with chemotherapy (not reached vs. 0.6 years, respectively; P=0.002). Excluding patients with inv(16) with trisomy 22, our data indicate that compathe outcome of CBF-AML patients with FLT3-ITD may be inferior to that of patients without FLT3-ITD (based on previously published data), suggesting that prognostically CBF-AML patients with FLT3-ITD should not be classified as favorable-risk. FLT3-inhibitors may improve the outcome of these patients.

CIBERONC Instituto Carlos 3 Madrid

Department of Clinical Haematology Centro Hospitalar e Universitário de Coimbra Coimbra

Department of Internal Medicine 5 Heidelberg University Hospital Heidelberg

Department of Internal Medicine 5 Heidelberg University Hospital Heidelberg Germany

Department of Internal Medicine and Haematology 3rd Faculty of Medicine Charles University and Faculty Hospital Kralovske Vinohrady Charles University Prague Czech Republic

Department of Internal Medicine Hematology and Oncology Masaryk University and University Hospital Brno Brno Czech Republic

Department of Medical Oncology Dana Farber Cancer Institute Boston MA

Department of Medical Oncology National Center for Tumor Diseases Heidelberg University Hospital Heidelberg

Department of Medicine 1 University Hospital Carl Gustav Carus Dresden

Division of Hematology and Oncology Abramson Cancer Center Perelman School of Medicine at the University of Pennsylvania Philadelphia PA

Division of Hematology Department of Internal Medicine Mayo Clinic Rochester Minnesota

Hematology Department Hospital Universitari i Politècnic La Fe València Spain

Hospital General Alicante

Institute of Hematology and Blood Transfusion Prague Czech Republic

Laboratory for Leukemia Diagnostics Department of Medicine 3 University Hospital LMU Munich Munich

Massachusetts General Hospital Boston MA

Medical Clinic and Policlinic 1 Hematology and Cellular Therapy University Hospital Leipzig Leipzig

Medical Clinic and Policlinic 1 Hematology and Cellular Therapy University Hospital Leipzig Leipzig Germany

NCT Trial Center National Center of Tumor Diseases German Cancer Research Center Heidelberg Germany

Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore Maryland

000      

00000naa a2200000 a 4500

001      

bmc22018967

003      

CZ-PrNML

005      

20220804135225.0

007      

ta

008      

220720s2022 it f 000 0|eng||

009      

AR

024    7_

$a 10.3324/haematol.2021.278645 $2 doi

035    __

$a (PubMed)34348451

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a it

100    1_

$a Kayser, Sabine $u Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany; NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg. s.kayser@dkfz-heidelberg.de

245    10

$a Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study / $c S. Kayser, M. Kramer, D. Martínez-Cuadrón, J. Grenet, KH. Metzeler, Z. Sustkova, MR. Luskin, AM. Brunner, MA. Elliott, C. Gil, SC. Marini, Z. Ráčil, P. Cetkovsky, J. Novak, AE. Perl, U. Platzbecker, F. Stölzel, AD. Ho, C. Thiede, RM. Stone, C. Röllig, P. Montesinos, RF. Schlenk, MJ. Levis

520    9_

$a The aim of this study was to evaluate the prognostic impact of FLT3-ITD in core-binding factor acute myeloid leukemia (CBFAML) in an international, multicenter survey of 97 patients of whom 52% had t(8;21)(q22;q22) and 48% had inv(16)(p13q22)/t(16;16)(p13;q22). The median age of the patients was 53 years (range, 19-81). Complete remission after anthracycline-based induction (n=86) and non-intensive therapy (n=11) was achieved in 97% and 36% of the patients, respectively. The median follow-up was 4.43 years (95% confidence interval [95% CI]: 3.35-7.39 years). The median survival after intensive and non-intensive treatment was not reached and 0.96 years, respectively. Among intensively treated patients, inv(16) with trisomy 22 (n=11) was associated with a favorable 4-year relapse-free survival rate of 80% (95% CI: 59-100%) as compared to 38% (95% CI: 27-54%; P=0.02) in all other patients with CBFAML/ FLT3-ITD (n=75). Overall, 24 patients underwent allogeneic hematopoietic cell transplantation (HCT), 12 in first complete remission and 12 after relapse. Allogeneic HCT in first complete remission was not beneficial (P=0.60); however, allogeneic HCT seemed to improve median survival in relapsed patients compared to that of patients treated with chemotherapy (not reached vs. 0.6 years, respectively; P=0.002). Excluding patients with inv(16) with trisomy 22, our data indicate that compathe outcome of CBF-AML patients with FLT3-ITD may be inferior to that of patients without FLT3-ITD (based on previously published data), suggesting that prognostically CBF-AML patients with FLT3-ITD should not be classified as favorable-risk. FLT3-inhibitors may improve the outcome of these patients.

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a transkripční faktor PEBP2 $x genetika $7 D050660

650    12

$a transplantace hematopoetických kmenových buněk $7 D018380

650    _2

$a lidé $7 D006801

650    12

$a akutní myeloidní leukemie $x diagnóza $x genetika $x terapie $7 D015470

650    _2

$a lidé středního věku $7 D008875

650    _2

$a mutace $7 D009154

650    _2

$a prognóza $7 D011379

650    _2

$a indukce remise $7 D012074

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a mladý dospělý $7 D055815

650    _2

$a tyrosinkinasa 3 podobná fms $x genetika $7 D051941

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

700    1_

$a Kramer, Michael $u Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden

700    1_

$a Martínez-Cuadrón, David $u Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain; CIBERONC, Instituto Carlos III, Madrid

700    1_

$a Grenet, Justin $u Division of Hematology and Oncology, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

700    1_

$a Metzeler, Klaus H $u Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich

700    1_

$a Sustkova, Zuzana $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic

700    1_

$a Luskin, Marlise R $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

700    1_

$a Brunner, Andrew M $u Massachusetts General Hospital, Boston, MA

700    1_

$a Elliott, Michelle A $u Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

700    1_

$a Gil, Cristina $u Hospital General, Alicante

700    1_

$a Marini, Sandra Casal $u Department of Clinical Haematology, Centro Hospitalar e Universitário de Coimbra, Coimbra

700    1_

$a Ráčil, Zdeněk $u Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Institute of Hematology and Blood Transfusion, Prague, Czech Republic

700    1_

$a Cetkovsky, Petr $u Department of Internal Medicine and Haematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Charles University Prague, Czech Republic

700    1_

$a Novak, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic

700    1_

$a Perl, Alexander E $u Division of Hematology and Oncology, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

700    1_

$a Platzbecker, Uwe $u Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig

700    1_

$a Stölzel, Friedrich $u Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden

700    1_

$a Ho, Anthony D $u Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg

700    1_

$a Thiede, Christian $u Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden

700    1_

$a Stone, Richard M $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

700    1_

$a Röllig, Christoph $u Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden

700    1_

$a Montesinos, Pau $u Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain; CIBERONC, Instituto Carlos III, Madrid

700    1_

$a Schlenk, Richard F $u NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg

700    1_

$a Levis, Mark J $u Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland

773    0_

$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 107, č. 4 (2022), s. 836-843

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34348451 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220720 $b ABA008

991    __

$a 20220804135219 $b ABA008

999    __

$a ok $b bmc $g 1822524 $s 1170210

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 107 $c 4 $d 836-843 $e 20220401 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963

GRA    __

$a P50 CA100632 $p NCI NIH HHS $2 United States

LZP    __

$a Pubmed-20220720